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Abstract
Background: Von Willebrand disease (VWD) is not uncommon in Taiwan. In type 2 or type 3 VWD hemorrhagic
symptoms are severer and laboratory data relatively more distinctive. De novo mutation and somatic mosaicism of
type 2 VWD gene were rarely reported. Therefore clinical, laboratory and genetic studies of only type 2A, 2B and
2M VWD will be presented and issues of de novo mutation and somatic mosaicism will be explored.
Methods: Fifty-four patients belonging to 23 unrelated families from all around the country in whom type 2 VWD
exclusive of type 2N has been diagnosed not only by clinical and routine laboratory studies but also by genetic
confirmation during 1990–2015 were investigated. A novel technique named amplification refractory mutation
system-quantitative polymerase chain reaction (ARMS-qPCR) was used to confirm the presence of somatic
mosaicism. Informed consent was obtained for study.
Results: De novo mutation was identified in 4 families among 15 families (26.7 %) in whom family members
including parents were available for examination. All their parents were free from bleeding symptoms and had no
similar mutation as their respective affected daughter.
An interesting example of somatic mosaicism of VWF gene mutation was found in a large family with type 2A
VWD. The father carrying a mutated VWF gene, p.Arg1597Trp, transmitted this mutation to his 3 daughters, 1 son,
3 granddaughters and 2 grandsons. However, the father had normal laboratory findings and experienced no
abnormal bleeding, while his offspring who inherited the mutation showed abnormal laboratory findings
compatible with type 2A VWD and had history of abnormal bleedings. ARMS-qPCR revealed that the father had
only 25.5 % mutant in his blood cells and 31.1 % mutant in his oral mucosal cells, while all his offspring had about
49 % mutant in their blood cells.
Conclusion: De novo mutation of type 2 VWD gene was identified in 4 out of 15 families (26.7 %) examined. Since
only one child was affected in each family, germline mosaicism was not likely. A somatic mosaicism of type 2A
VWD gene was documented in a big family by a newly in-house developed technique ARMS-qPCR.
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Background
von Willebrand disease (VWD) is a genetically and clin-
ically heterogeneous inherited hemorrhagic disorder
caused by a deficiency or dysfunction of von Willebrand
factor (VWF). VWD is considered to be the most com-
mon hereditary bleeding disorder [1, 2]. VWD is perhaps
not uncommon in Taiwan, however, it has not been well
studied. In type 2 and type 3 VWD, hemorrhagic symp-
toms are severer and laboratory data relatively more dis-
tinctive, which lead to diagnose the patient easily [3, 4].
Almost all the mutations detected in type 2 VWD in-
cluding type 2A, 2B and 2M exhibit autosomal dominant
inheritance patterns and is transmitted from either of
their parents [3]. However, there was quite few de novo
mutation of the type 2 VWD gene reported [5], somatic
mosaicism of the type 2 VWD gene was even more
rarely reported [3], despite it had been mentioned in
hemophilia B [6]. Herein clinical, laboratory and genetic
studies of only type 2 VWD exclusive of type 2N seen in
Taiwan were investigated, which demonstrated a not-so-
uncommon occurrence of de novo mutation. In this
study we cited an interesting example from a big family
suffered from type 2A VWD, in which somatic mosai-
cism of the VWF gene mutation will be presented.
Methods
Fifty-four patients from 23 unrelated families in whom
type 2 VWD has been diagnosed not only by clinical and
laboratory studies but also by genetic confirmation dur-
ing 1990 to 2015 at National Taiwan University Hospital
and Changhua Christian Hospital, all tertiary referred
hospitals, were investigated. A revised classification of
VWD described by Salder JE et al. in 2006 [7] and cri-
teria for the diagnosis of type 2 VWD and its subtypes
given by Federici AB in 2014 [8] were used. Factor VIII
coagulant activity (VIII:C) was assayed according to the
one-stage method. von Willebrand factor antigen
(VWF:Ag) was determined by a two-step enzyme im-
munoassay sandwich method with a final fluorescent de-
tection (ELFA) (VIDAS; bioMérieux, Marcy-I’Étoile,
France) [9]. von Willebrand factor activity (VWF:Act)
was measured by a latex particle enhanced immunotur-
bidimetric assay (Instrumentation Laboratory, Lexington,
MA, USA). The latex particle was absorbed onto a specific
anti-VWF monoclonal antibody directed against the
platelet binding site of VWF, i.e. glycoprotein Ib receptor
[10, 11]. VWF multimer analysis was performed as
described previously [12]. A novel technique named amp-
lification refractory mutation system-quantitative poly-
merase chain reaction (ARMS-qPCR), which was
developed for both preimplantation genetic diagnosis and
prenatal genetic diagnosis [13, 14], was used to confirm
the presence of somatic mosaicism, because it can accur-
ately quantify the number of copies of a particular ampli-
con, and determine the ratio of mutant to wild-type alleles
in a sample, all using purified DNA as s test sample. Exons
and its junction of full length VWF gene were amplified
and sequenced as previously described [15]. Informed
consent was obtained from patients and family members.
Results
Novel mutation in the type 2 VWD
We have seen 54 patients from 23 unrelated families in
whom type 2 VWD has been diagnosed during 1990 to
2015, including 35 patients from 11 families of type 2A
VWD, 8 patients from 5 families of type 2B VWD and 11
patients from 7 families of type 2M VWD. Type 2N VWD
was not found. Among them 19 were male, 35 female; their
ages of diagnosis ranged from 1 to 67 years with a median
of 24 years. There were no statistical differences in gender
and age of diagnosis between various types of VWD.
Eleven different previously reported mutations of the
VWF gene based on the ISTH-SSC VWF database, as
accessed in June 2016, was identified in the 16 index
patients with type 2 VWD including 6 mutations from 8
type 2A VWD patients: p.Arg1374His, p.Ser1506Leu,
p.Cys1272Gly, p.Arg1597Trp, p.Cys1272Arg and p.Ile16
28Thr; 3 mutations from 5 type 2B VWD patients:
p.Arg1306Trp, p.Val1316Met and p.Arg1308Cys; and 2
mutations from 3 type 2M VWD patients: p.Arg1374Cys
and p.Arg1315Cys. Six different novel mutations of the
VWF gene also according to the ISTH-SSC VWF data-
base was identified in the 7 index patients with type 2
VWD including 3 mutations from 3 type 2A VWD pa-
tients: p.Leu1696del, p.Glu1519del and p.Ala1500Val;
and 3 mutations from 4 type 2M VWD patients: c.5312-
1 ~ −2del AG, p.Leu1276Arg and c.3538 + 1G→ C.
De novo mutation in the type 2 VWD
De novo mutations of VWF gene were detected in 4 fam-
ilies, one of them was novel. All their parents were free
from bleeding symptoms and had no similar mutation as
their respective affected daughter. The paternity tests
were done in these 4 couples of parents after informed
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consents were obtained, the kinship were confirmed.
The clinical, laboratory and genetic data of these 4 pa-
tients were shown in Table 1.
Somatic mosaicism of type 2A VWD gene
An interesting example of somatic mosaicism of VWF
gene mutation was found in a large family afflicted with
type 2A VWD. The father carrying a mutated VWF
gene, c.4789C→ T, p.Arg1597Trp, transmitted this mu-
tation to his 3 daughters, 1 son, 3 granddaughters and 2
grandsons. However, as shown in Fig. 1, the father had
normal levels of FVIII:C, VWF:Ag and VWF:Act and ex-
perienced no abnormal bleeding, while his 3 daughters,
1 son and 5 grandchildren who inherited the mutation















Family history and affected
sibling in the family
8/F Type 2A 28 (A2) c.4517 C→ T p.Ser1506 Leu 53 38.5 10 None
12/F Type 2B 28 (A1) c.3916 C→ T p.Arg1306Trp 27 50 7.5 None
10/F Type 2B 28 (A1) c.3922 C→ T p.Arg1308Cys 31 35.9 4.5 None
7/Fa Type 2M 28 (A1) c.3827T→ G p.Leu1276Argb 28 26 6 None
aF: female
bNovel mutation
Fig. 1 Clinical and laboratory studies as well as amplification refractory mutation system-qPCR(ARMS-qPCR) examination of a family of type 2A
VWD with somatic mosaicism of the VWD gene mutation. The father carrying a mutated VWF gene transmitted this mutation to his offspring
except the elder son. The father had normal VWF level and experienced no abnormal bleeding but all his offspring who inherited the mutation
showed abnormal laboratory findings of type 2A VWD and all had histories of abnormal bleeding. The results of ARMS-qPCR showed that father
had only 25.5 % mutant in his blood cells and 31.1 % mutant in his oral mucosal cells. However, all of his offspring had about 49 % mutant in
their blood cells. The arrow indicates the C/T substitution
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of VWF gene from the father showed abnormal labora-
tory findings and VWF multimer analysis (data not
shown) compatible with type 2A VWD and all had his-
tories of abnormal bleedings. In order to determine the
ratio of mutant (MU) to wild-type (WT) alleles in vari-
ous tissues from family members, ARMS-qPCR was
used. As shown in Fig. 1, the father had only 25.5 % mu-
tant in his blood cells and 31.1 % mutant in his oral mu-
cosal cells, while all his offspring had about 49 % mutant
in their blood cells. These findings were compatible to
the height of sequence curve of nucleotide C/T as indi-
cated by an arrow in the Fig. 1. The ratio of mutant (%)
in each sample as shown above was estimated based on
a standard curve generated by plotting the difference be-
tween the PCR cycle crossing point (Cp) of the WT al-
lele and the MU allele i.e. ΔCp (WT-MU) value of
different synthetic dilutions against the mutant % of the
synthetic dilution (Fig. 2a). The synthetic dilutions were
prepared by a 2-fold serial dilution of MU DNA by WT
DNA. The ARMS-qPCR results for the family afflicted
with type 2A VWD were showed in Fig. 2b-e.
Discussion
Seven out of 23 index patients (30.4 %) or 11out of 54
patients (20.4 %) available for examination showed novel
mutations of VWF gene. With a large size of the VWF
gene, this high degree of new variant can be expected.
Although we consider these normal variants as novel
mutations, their pathogenicity for VWD has to be con-
firmed by linkage analysis or structure-function studies
of VWF gene, otherwise some nucleotide changes may
be neutral in phenotype and can only be called as a poly-
morphism. In addition, the pathogenetic basis of some
of the changes are also unclear.
De novo mutation has been identified in 4 families
among 15 families (26.7 %) in whom family members in-
cluding parents were available for examination. De novo
mutation is a rare event in VWD [5]. However, some
multicenter studies on type 1 VWD had identified de
novo mutation in at least 2–4 % of proband [16–18].
Such high incidence (26.7 %) of de novo mutation in
type 2 VWD patients exclusive of type 2N in the present
study can be a selection bias or due to small number of
patients studied. Two possible explanations for the oc-
currence of de novo mutation are a true event, or results
of a new mutation coexisting with a germline mosaicism
in a parent, or somatic mosaicism [18]. If more than one
child is affected by so called de novo mutation with the
same mutant, germline mosaicism can be rationally
speculated, because the chance of de novo mutation with
a same genetic defect in two children must be extremely
rare [18, 19]. Only one child is affected in each family as
found in the 4 families we identified (Table 1), the ex-
planation for this may be a de novo mutation or a
germline mutation with a transmissible mutant, or som-
atic mosaicism, unless we are able to obtain a genital tis-
sue for confirmatory analysis. If there is a single
affected offspring, germline mosaicism still cannot be
excluded, this will depend upon the extent of the mo-
saic germ cell, a factor that is often impossible to
quantify. Germline or gonadal mosaicism has been
detected in type 2B VWD [19].
We have found an interesting example of somatic mo-
saicism of VWF gene in a large family with type 2A
VWD with a previously reported VWF gene mutation.
There are some key features of autosomal dominant in-
heritance, i.e., variable expressivity, incomplete or non-
penetrance and anticipation. However, there is a general
belief that type 2A, 2B and maybe 2M VWD mutations
are fully penetrant [3], and are also not associated with
variable expressivity. This is in marked contrast with
type 1 VWD where all of these genetic variances are
common for many mutations, and correlation between
genotype and phenotype is difficult [3, 20]. Meanwhile,
key features of an autosomal dominant inheritance pat-
tern involves variable expression, incomplete penetrance
and anticipation are not associated with type 2 forms of
VWD [personal communication with Dr. David
Lillicrap].
In this index family of VWD, the father carries the
mutant allele but remains asymptomatic throughout his
life, while all his children and grandchildren who carry
the mutation have abnormal bleeding phenotype, namely
patients of VWD. Somatic mosaicism can thus be attrib-
uted to this extraordinary presentation of this autosomal
dominant disorder since the percentage of the VWF-
producing progenitor cells of the vascular endothelium
may be very low. From the patients and unaffected
mother, the mutant allele versus the wild-type allele fol-
lows the classical 50 %:50 % and 0 %:100 %, respectively.
However, either the real-time PCR data obtained from
the asymptomatic “mutant carrier” were much deviated
from 50 %, i.e., 25.5 % in the peripheral blood and
31.1 % in the oral mucosa. This is the undisputed evi-
dence of the existence of “somatic mosaicism”. We
therefore speculate that the cell/tissue which are respon-
sible for coding VWF, e.g. vascular endothelial cell or
megakaryocyte are carrying the wild-type alleles only,
instead of mutant alleles. Such somatic mosaicism have
been proved in other disorder such as Dravet syndrome
[21 and hemophilia B [6].
Conclusion
Seven out of 23 index patients (30.4 %) examined
showed novel mutations or normal variants of VWF
gene. De novo mutation of type 2 VWD gene was identi-
fied in 4 families among 15 families (26.7 %) in whom
family members were available for examination. Only
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Fig. 2 ARMS‐qPCR for the point mutation c.4789C > T (p.Arg1597Trp) of VWF gene. A standard curve was generated by plotting the difference
between the PCR cycle crossing point (Cp) of the wild-type (WT) allele and the mutant (MU) allele i.e. ΔCp (WT-MU) value of different synthetic
dilutions against the mutant % of the synthetic dilution. The synthetic dilution were prepared by a 2-fold serial dilution of MU DNA by WT DNA.
(a). According to the S‐curve formula, amplification plot was analyzed at genomic level of an affected family with the paternally‐inherited
c.4789C > T mutation to detect the mutant % in different samples of maternal blood (b), the proband (affected children) blood (c), paternal blood
(d) and oral mucosal cells (e), and the results showed 0 %, 49 %, 25.5 % and 31.1 % in mutant percentage, respectively. Triplicated ARMS‐qPCR
tests with WT allele‐specific primers are indicated by WT lines in one color, whereas the tests with MU allele‐specific primers are indicated by MU
lines in another color
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one child was affected in each family. Germline mosai-
cism is therefore unlikely although its possibility cannot
be totally excluded. Somatic mosaicism of VWF gene
mutation was documented in a large family with type 2A
VWD with a previously reported VWF gene pathogenic
mutation, p.Arg 1597Trp. This extraordinary presenta-
tion was confirmed by a newly developed technique
named ARMS qPCR.
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